Clinical Leadership

We have built a large, expert team to design and manage our clinical trials, the vital and lengthy phase following discovery and preclinical development.

Our Clinical Development and Regulatory Affairs group has more than 400 team members, including many with doctoral degrees and years of pharmaceutical-industry experience.

Peter Powchik, M.D. Peter Powchik, M.D.
SVP, Clinical Development

Bola Akinlade Bola Akinlade, M.D., M.B.A., F.A.C.P.
Executive Director, Clinical Sciences

Ned Braunstein Ned Braunstein, M.D. 
SVP, Regulatory Affairs

Ingrid Adamsons, M.D., M.P.H. Ingrid Adamsons, M.D., M.P.H.
VP Pharmacovigilance and Risk Management

Graeme Currie Graeme Currie, Ph.D.
VP Clinical Project Management and Operations

Israel Lowy Israel Lowy, M.D., Ph.D.
VP Translational Science and Oncology

Daniel Matarazzo Daniel Matarazzo, M.B.A.
Senior Director Clinical Finance

Scott Mellis Scott Mellis, M.D., Ph.D.
VP Clinical Sciences, Translational Medicine

Robert Pordy Robert Pordy, M.D., FACP
VP Clinical Sciences, Cardiovascular and Metabolism

Yuhwen Soo Yuhwen Soo, Ph.D.
VP Biostatistics and Data Management

Catherine Stehman-Breen Catherine Stehman-Breen, M.D., M.S.
VP Clinical Sciences

Beate Stych Beate Stych, M.D.
VP Medical Affairs

Janet van Adelsberg Janet van Adelsberg, M.D.
Senior Director, Immunology and Inflammation

Robert Vitti Robert Vitti, M.D., M.B.A.
VP Clinical Sciences, Ophthalmology

This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.

Form content here please :)